Arch Biopartners, Inc. · TSXV:ARCH

Arch Biopartners — Investor Presentation (January 2026)

19 slides from Arch Biopartners's investor presentation, January 2026

  1. Slide 1: New Drugs for Acute Kidney Injury and Chronic Kidney Disease

    TSXV: ARCH.V OTCQB: ACHFF.US New Drugs for Acute Kidney Injury and Chronic Kidney Disease January 2026 www.archbiopartners.com

  2. Slide 2: Notes about forward looking statements

    Notes about forward looking statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of our future performance, liquidity and capital resources, as well as the ongoing clinical development of our drug candidates

  3. Slide 3: A critical gap in kidney treatment

    A critical gap in kidney treatment There is a lack of effective treatments to prevent or stop the progression of acute kidney injury (AKI) and chronic kidney disease (CKD). Patients with kidney failure must undergo dialysis while waiting for a kidney transplant in order to survive. Arch Biopartners

  4. Slide 4: Millions face acute and chronic kidney disease every year

    Millions face acute and chronic kidney disease every year Acute Kidney Injury (AKI) Chronic Kidney Disease (CKD) ■ Affects approximately 14–16 million ■ More than 800 million people globally, people each year in the U.S. and E.U.1, 2 have chronic kidney disease – the ■ No approved treatments; patien

  5. Slide 5: Arch has two AKI drugs in Phase II and a next generation CKD platform

    Arch has two AKI drugs in Phase II and a next generation CKD platform. Two Phase II clinical trials focused on AKI, which Next generation affects millions of patients each year. drugs for CKD. LSALT peptide (Phase II) Cilastatin (Phase II) CKD Platform Addressing inflammation Repurposing cilastatin T

  6. Slide 6: LSALT peptide is in a Phase II trial to protect kidneys from CS-AKI

    LSALT peptide is in a Phase II trial to protect kidneys from CS-AKI. Up to 30% of cardiac surgery (CS) patients on bypass machines experience acute kidney injury (AKI).3,4 ■ Over one million cardiac surgeries, ■ Phase II trial, designed for up to 240 including bypass procedures, are patients, curren

  7. Slide 7: LSALT peptide targets Dipeptidase-1 (DPEP1)

    LSALT peptide targets Publication in CELL Dipeptidase-1 (DPEP1). Targeting a novel pathway to block kidney inflammation Arch Scientists’ publication Watch LSALT peptide in Cell (2019): DPEP1 preventing inflammation: mediates white blood cell Kidney protected Inflammatory adhesion in the kidney, with LS

  8. Slide 8: Cilastatin: a repurposed DPEP1 inhibitor in a Phase II trial for drug toxin-induced AKI

    Cilastatin: a repurposed DPEP1 inhibitor in a Phase II trial for drug toxin-induced AKI. Drug toxin-induced AKI is a common complication of widely used antibiotics, chemotherapy, and other nephrotoxic drugs, with no approved treatments. The PONTiAK trial is testing cilastatin to The study is indepen

  9. Slide 9: Repurposing cilastatin as a treatment for drug-induced AKI

    Repurposing cilastatin as a Publication in NKF: Kidney Medicine treatment for drug-induced AKI Cilastatin inhibits nephrotoxin uptake by kidney cells, an off-target effect that may prevent AKI caused by widely used antibiotics, chemotherapy drugs, and contrast agents used in medical imaging. Pre-cli

  10. Slide 10: Arch's third asset: a next generation chronic kidney disease drug platform

    Arch’s third asset: a next generation chronic kidney disease drug platform. Arch’s CKD platform targets interleukin-32 (IL-32), a human cytokine directly implicated in kidney inflammation and diabetic kidney disease (DKD). ■ 800M people affected globally; Arch’s IL-32 strategy advances a 35–38M in th

  11. Slide 11: IL-32 as a novel driver of diabetic kidney disease

    IL-32 as a novel driver of Abstract in JASN diabetic kidney disease Interleukin-32 (IL-32) has been identified as a potential mediator of lipid droplet accumulation and chronic inflammation in kidney cells, key processes underlying diabetic kidney disease (DKD), the leading cause of kidney failure wor

  12. Slide 12: Arch's leadership in kidney therapeutics is protected by strong patents

    Arch’s leadership in kidney therapeutics is protected by strong patents. LSALT peptide Cilastatin CKD Platform Composition and Method-of-use patents Patents covering both method-of-use patents. to repurpose cilastatin composition and Approval for the CS-AKI as a treatment to prevent method-of-use fo

  13. Slide 13: Next steps: Completing Phase II AKI trials and advancing the IL-32 CKD program

    Next steps: Completing Phase II AKI trials and advancing the IL-32 CKD program. Arch’s programs target the leading causes of acute and chronic kidney injury, addressing millions of patients worldwide. The CS-AKI and PONTiAK Phase II trials Arch’s IL-32 CKD program highlights a target up to 60% of al

  14. Slide 14: Investor Information

    Investor Information Latest news highlights, read and subscribe online. Read the latest news releases and download financial December 16, 2025 reports and filings (also at SEDAR+). Ethics Approval for St. Michael’s Hospital to www.archbiopartners.com/investor-hub Participate in the Phase II CS-AKI Tri

  15. Slide 15: Executive Management

    Executive Management Richard Muruve Andrew Bishop Dr. Daniel Muruve MD CEO, Director, Co-founder CFO, Director CSO, Co-Founder Mr. Muruve co-founded the Mr. Bishop is a Partner and A Professor in the Dept. of company with the Arch Co-Founder of Bingley Capital Medicine at the University of Inflammati

  16. Slide 16: A committed board and advisors

    A committed board and advisors. Claude Allary, Director Farris Smith, Strategic Advisor Co-founder, partner of Bionest Consulting, President, Vimy Pharma, Former CFO, Leo Sanofi, Pfizer, Glaxo Pharma (North America), Novo Nordisk Canada. Richard Rossman, Director Patrick Vink, Strategic Advisor Gastro

  17. Slide 17: Contact us for more information

    Contact us for more information. Contact us Latest news releases +1 647 428-7031 office archbiopartners.com/investor-hub/press-releases info@archbiopartners.com X (Twitter): About the company https://x.com/archbiopartners archbiopartners.com/about-us LinkedIN Investor information https://bit.ly/ArchBi

  18. Slide 18: Sources

    Sources 1. Sawhney, S., et al. Harmonization of epidemiology of acute kidney injury and acute kidney disease produces comparable findings across four geographic populations. Kidney International, Volume 101, Issue 6, 1271 - 1281. https://doi.org/10.1016/j.kint.2022.02.033 2. Pavkov M.E., et al. Trend

  19. Slide 19: Sources Cont.

    Sources Cont. 10. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022 Apr;12(1):7-11. Epub 2022 Mar 18. PMID: 35529086; PMCID: PMC9073222 https://doi.org/10.1016/j.kisu.2021.11.003 11. Francis, A., Harhay, M.N., Ong, A.C.M. et al. Chronic kidney disease

Arch Biopartners — Investor Presentation (January 2026) on 6ix